Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Deciphera Announces the Opening of a New Office in Zug, Switzerland
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
U.S. FDA Grants Full Approval of Deciphera's ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH
ONO to buy Deciphera Pharmaceuticals at a huge premium
ONO to buy Deciphera Pharmaceuticals at a huge premium
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 71%
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders
Deciphera to be acquired by Japan's Ono in all-cash deal valued at $2.4 billion
Japan's ONO Pharmaceutical to buy Deciphera for $2.4 billion
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
GENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern Europe
Deciphera: Upside Potential For The Patient Investor
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
Deciphera Pharmaceuticals: Moving The Needle Where It Counts
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results